Shares of Summit Therapeutics Inc. SMMT jumped more than 270% Thursday after the company said its experimental cancer drug outperformed Merck & Co. Inc.’s blockbuster Keytruda in a late-stage clinical ...
A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer. Merck has ...
Acceptance based on results from the Phase 3 KEYNOTE-091 trial, the seventh positive pivotal study evaluating a KEYTRUDA-based regimen in earlier stages of cancer The study has dual primary endpoints ...
Merck & Co.’s Keytruda has long been viewed as a standard of care in metastatic non-small cell lung cancer (NSCLC). Now, the PD-1 king has scored the FDA’s permission to enter early-stage disease with ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, New Jersey (Reuters) -The U.S. Food ...
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck’s anti-PD-1 ...
The Phase III trial named Harmoni-2 was held in China, in conjunction with Summit's partner Akeso. In the trial, Ivonescimab and Keytruda were administered as a monotherapy to patients with locally ...
The Food and Drug Administration approved Keytruda, an immunotherapy agent, for patients with stage 1B, 2 or 3A non-small cell lung cancer. The Food and Drug Administration (FDA) approved Keytruda ...
Keytruda is approved for early-stage non-small cell lung cancer post-surgery and chemotherapy, improving disease control and survival by 27%. The drug works by enhancing immune system recognition of ...
Thursday, Merck & Co Inc (NYSE:MRK) released topline data from the Phase 3 KEYLYNK-006 trial evaluating Keytruda (pembrolizumab) in combination with maintenance Lynparza (olaparib) for certain ...
Merck & Co., Inc. MRK presented encouraging five-year survival data on its PD-L1 inhibitor, Keytruda in patients with advanced non-small cell lung cancer (NSCLC) at the annual meeting of American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results